Interpace Diagnostics Group (IDXG) AI Stock Analysis

• Market Cap: $3.98M
• Dividend Yield: N/A
• Average Volume (3M): 3.19K
• Price to Earnings (P/E): 0.8
• Beta (1Y): 2.19
• Revenue Growth: 17.33%
• EPS Growth: N/A
• Country: US
• Employees: 108
• Sector: Healthcare
• Sector Strength: 76
• Industry: Medical - Diagnostics & Research
• EPS (TTM): 1.19
• Shares Outstanding: 4,423,093
• 10 Day Avg. Volume: 4,815
• 30 Day Avg. Volume: 3,191
• PEG Ratio: 0.00140
• Price to Book (P/B): N/A
• Price to Sales (P/S): 0.12
• Price to Cash Flow (P/CF): 0.60
• P/FCF Ratio: 0.80
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

Interpace Diagnostics Group presents a mixed outlook. The company shows strong revenue growth and profitability, but its financial stability is a concern due to negative equity. Technical indicators signal bearish trends, while the stock appears undervalued based on its P/E ratio. Investors should weigh these factors carefully, considering the financial risks and current market sentiment.

Interpace Diagnostics Group Business Overview & Revenue Model

Company Description

Interpace Diagnostics Group (IDXG) is a company operating in the healthcare sector, specializing in molecular diagnostics and clinical services. It provides diagnostic tests and pathology services aimed at detecting and managing cancer and other diseases. The company's core offerings include proprietary molecular and diagnostic tests that help in identifying the risk of cancer progression, which aids physicians in making more informed treatment decisions.

How the Company Makes Money

Interpace Diagnostics Group generates revenue primarily through the sale of its diagnostic testing services to healthcare providers, laboratories, and other medical institutions. The company's key revenue streams include fees charged for its diagnostic tests and related pathology services. These services are critical for the early detection and management of various types of cancer, thus providing value to its clients. Additionally, Interpace may enter into partnerships with healthcare organizations, insurance companies, and research institutions to expand its market reach and enhance its service offerings, which can also contribute to its revenue growth. The company may also receive reimbursement from insurance providers for tests covered under patients' health plans, further impacting its revenue positively.

Interpace Diagnostics Group Financial Statement Overview

Summary

Interpace Diagnostics Group demonstrates solid operational performance with improved profitability and revenue growth, bolstering its income statement. However, the balance sheet reflects significant financial risk due to negative equity, which could impact long-term stability. The cash flow position is improving, indicating efficient cash management and potential for future growth. Overall, while there are promising signs of recovery and growth, financial risks remain due to historical losses.

Income Statement

Interpace Diagnostics Group shows a significant improvement in profitability metrics over the TTM (Trailing-Twelve-Months). The gross profit margin stands at 60.41%, and the net profit margin is 10.47%, indicating efficient cost management and a strong bottom line. Moreover, there's a robust revenue growth rate of 11.61% compared to the previous year, evidencing strong demand and market position. However, the EBIT margin at 14.16% is moderate, suggesting room for operational improvements.

Balance Sheet

The balance sheet indicates high financial risk, with a negative stockholders’ equity of -$11.15 million, reflecting accumulated losses. The debt-to-equity ratio is not applicable due to negative equity, but the total debt of $1.19 million compared to total assets of $14.04 million is relatively manageable. The equity ratio is negative, which is concerning as it suggests financial instability and reliance on liabilities.

Cash Flow

The cash flow statement shows positive developments, with a strong operating cash flow to net income ratio of 0.98, indicating efficient cash generation from operations. The free cash flow has increased by 11.86% over the previous year, reflecting better capital management. However, the free cash flow to net income ratio is lower at 0.79, suggesting that not all earnings translate into free cash flow, though the improvement trajectory is favorable.

Breakdown
TTM	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019
Income Statement		Total Revenue
44.89M	40.21M	31.84M	41.31M	32.40M	24.08M
	Gross Profit
27.12M	23.90M	18.23M	17.95M	10.72M	8.19M
	EBIT
6.36M	2.80M	-3.84M	-11.74M	-26.55M	-23.93M
	EBITDA
6.17M	3.84M	-2.27M	-1.33M	-20.10M	-21.72M
	Net Income Common Stockholders
4.70M	802.00K	-5.87M	-14.75M	-26.20M	-26.64M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
72.83M	3.50M	4.83M	3.31M	2.77M	2.32M
	Total Assets
106.32M	13.02M	15.98M	38.43M	45.68M	69.05M
	Total Debt
0.00	11.19M	16.09M	13.72M	4.74M	7.10M
	Net Debt
-72.69M	7.69M	11.26M	10.40M	1.97M	4.78M
	Total Liabilities
32.79M	28.16M	79.05M	80.84M	74.76M	56.02M
	Stockholders Equity
73.53M	-15.14M	-63.07M	-42.42M	-29.08M	13.03M
Cash Flow		Free Cash Flow
3.71M	3.32M	-8.01M	-9.07M	-16.15M	-19.09M
	Operating Cash Flow
4.60M	3.79M	-7.69M	-8.72M	-14.58M	-18.96M
	Investing Cash Flow
-889.00K	-87.00K	6.21M	-315.00K	-1.57M	-13.95M
	Financing Cash Flow
-6.63M	-5.03M	3.00M	8.98M	16.61M	29.16M

Interpace Diagnostics Group Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.90
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IDXG, the sentiment is Negative. The current price of 0.9 is below the 20-day moving average (MA) of 1.12, below the 50-day MA of 1.19, and below the 200-day MA of 1.75, indicating a bearish trend. The MACD of -0.05 indicates Positive momentum. The RSI at 33.40 is Neutral, neither overbought nor oversold. The STOCH value of 16.67 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IDXG.

Interpace Diagnostics Group Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CDNA	68 Neutral	$957.76M	16.99	19.46%	―	19.07%	―
IDXG	58 Neutral	$3.98M	0.76	-42.17%	―	17.33%	―
FLGT	56 Neutral	$520.40M	―	-3.76%	―	-1.99%	74.89%
MYGN	51 Neutral	$742.34M	―	-17.15%	―	12.15%	61.33%
Sector *	48 Neutral	$6.36B	1.09	-49.92%	2.63%	17.17%	0.95%
QDEL	46 Neutral	$1.90B	―	-50.74%	―	-7.03%	-20233.78%